Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Remington

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
Expert Opinion on Drug Safety|May 22, 2016
Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and useG Remington, J Lee, O Agid, et al.
Molecular Psychiatry|September 4, 2007
Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patientsC C Zai, V De Luca, R W Hwang, et al.
Journal of Clinical Psychopharmacology|February 1, 1993
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patientsG Chouinard, B Jones, G Remington, et al.
Psychological Medicine|July 29, 2014
Prenatal maternal immune disruption and sex-dependent risk for psychosesJ M Goldstein, S Cherkerzian, L J Seidman, et al.
Molecular Psychiatry|November 29, 2007
Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophreniaJ Renou, V De Luca, C C Zai, et al.
The Pharmacogenomics Journal|January 27, 2011
Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesiaA K Tiwari, C C Zai, O Likhodi, et al.
The Pharmacogenomics Journal|February 25, 2009
Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patientsC C Zai, A K Tiwari, V Basile, et al.
Parkinsonism & Related Disorders|February 4, 2025
Tardive dyskinesia versus tardive syndrome. What is in a name?Karen Frei, Alicia Scott, Stanley N Caroff, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Expert Opinion on Drug Safety|May 22, 2016
Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and useG Remington, J Lee, O Agid, et al.
Molecular Psychiatry|September 4, 2007
Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patientsC C Zai, V De Luca, R W Hwang, et al.
Journal of Clinical Psychopharmacology|February 1, 1993
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patientsG Chouinard, B Jones, G Remington, et al.
Psychological Medicine|July 29, 2014
Prenatal maternal immune disruption and sex-dependent risk for psychosesJ M Goldstein, S Cherkerzian, L J Seidman, et al.
Molecular Psychiatry|November 29, 2007
Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophreniaJ Renou, V De Luca, C C Zai, et al.
The Pharmacogenomics Journal|January 27, 2011
Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesiaA K Tiwari, C C Zai, O Likhodi, et al.
The Pharmacogenomics Journal|February 25, 2009
Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patientsC C Zai, A K Tiwari, V Basile, et al.
Parkinsonism & Related Disorders|February 4, 2025
Tardive dyskinesia versus tardive syndrome. What is in a name?Karen Frei, Alicia Scott, Stanley N Caroff, et al.
Pageof 10